| Biomarker ID | 572 |
| PMID | 21098088 |
| Year | 2011 |
| Biomarker | miR-106a, miR-93 and -1274a; miR-451; miR-1207-5p; miR-874 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miR-106a):- DNA-binding transcription factor activity, RNA polymerase II-specific; Gene expression (Transcription);RNA Polymerase II Transcription; Generic Transcription Pathway; DNA-binding transcription factor activity Pathways Include (miR-874):- synapse; synapse; nervous system development; enzyme binding; postsynapse |
| Experiment | Healthy Vs High Risk (CAPRA>5) |
| Type of Biomarker | Diagnostic |
| Cohort | A total of 48 patients, 12 heathy and 36 with prostate cancer (CAPRA score: CAPRA1 (n=12), CAPRA4 (n=12), CAPRA 5-7 (n=12)) were chosen for the study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | miR-106a p<0.001, miR-93 p<0.001; miR-1274a p<0.001; miR-451 p= 0.02; miR-1207-5p p<0.001; miR-874 p= 0.003 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | CAPRA score defined as: Cancer of the prostate risk assesment was based on the patients’ age, PSA level, clinical tumor stage, Gleason score, and percentage of biopsy cores positive for cancer at diagnosis, |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | miR-106a, miR-93, -1274a, miR-451, miR-1207-5p, miR-874 |